These are exciting times for Indian pharmaceutical market as the global demand for Indian made drugs continues to rise, particularly with Western economies looking to further expand their use of generics. The event will elevate India as the global pharmaceutical destination by showcasing the unique positioning of the Indian pharma market and provide an optimum investment platform amidst its global counterparts, says Joji George, MD, UBM India, in an email interview with AD Pradeep Kumar while giving an overview of the CP hI India event.
Kindly provide a brief on CPhI India 2014? Which edition is it, what is the theme for this edition, and how different would it be compared to the previous year? Number of visitors at CPhI 2013?
CPhI India 2014 is a three days industry event, wherein key players of the pharmaceutical sector, worldwide, will congregate to connect, share and ideate. The theme for this year’s edition is the emergence of India in the pharma sector and its vision to be a global leader by 2020. Last year, 27,237 attendees from 94 countries across the globe. The event witnessed a record participation of 1045 exhibitors from 21 countries that were spread over 55,000 sq. mts. in 8 exhibition halls of the Bombay Convention & Exhibition Centre, Mumbai, India.
What are the highlights of the event this year?
The main highlights of the year are the launch of India Pharma Market report by UBM & Global Business Reports, CPhI India Technical Seminar on industry trends & challenges. The event is also preceded by the 2nd Annual India Pharma Awards 2014, scheduled for 1st December 2014 at the Westin Hotel, Mumbai.
How many visitors are expected at the event? How will the event benefit them?
+ 28,000 industry executives from +95 countries are expected to attend the event this year. The event will provide a platform for professionals from across the industry to network, collaborate and showcase their products and services, and provide insights to the growing segments of the industry.
Which sectors/countries would the pavilions at the event represent?
We have two Pavilions. One represents the Pharmexcil pavilion of 85 companies, and the other is the China Chamber Pavilion.
Kindly share the detailed information about the workshops, seminars and conferences, and what topics to be discussed?
A series of technical seminars will take place throughout the show, providing detailed insights into current trends, issues and developments surrounding the pharma community.
The technical seminars this year discuss on topics such as ‘How to convert digital visitors into leads for your business – how digital advertising can benefit your company if done correctly, and disadvantages if done incorrectly’, ‘How small, medium and large organisations use digital advertising – how to improve your digital marketing campaigns’ and an insight into the future of digital advertising – what can we expect and how should we react.
Are there any co-located events with CPhI India 2014?
While CPhI India which is focused on pharmaceutical ingredients, it will be joined by co-located events: P-MEC India for pharmaceutical equipment, machinery and technology; ICSE India for contract services, clinical trials; and CRO and the BioPh trail for the biopharma market.
How many exhibitors are expected this year? What is the exhibitor profile?
The 8th edition of CPhI India 2014 will see 1000 plus exhibitors.
The event brings together professionals across the industry associated with Active Pharmaceutical Ingredients, Alkaloids, Amino acids, Antibiotics, Antibodies, Antimicrobial preservatives, Antioxidants, Biocatalysts, Biotechnology, Capsules/encapsulation, Chemical synthesis/analysis, Chira intermediates, Coating agents, Colour and dispersions, Custom manufacturing, Cytokines, Emulsifying/solubilising agents, Enzymes, Excipients and Drug formulation, Fine chemicals, Flavours and perfumes, Glidants, Herbal teas, Hormones & synthetic substances, Immunochemistry, Intermediates, Medicinal plants, Microencapsulation, Ointments bases, Peptides, Phospholipids, Plant/animal extracts, Prostaglandins, Publisher, Purification and separation techniques, Regulatory affairs, Sera and Vaccines, Solvents, Stiffening agents, Stiffening bases, Suppository bases, Suspending/viscosity, increasing agents, Sweetening agents, Synthetic organic chemistry, Tablet binders, Tablet disintegrants, Tablet filler-binders, Tablet lubricants, Tissue culture medias, Wetting/solubilising agents.
How many exhibitors are from India, and how many from overseas?
The 8th edition of CPhI India 2014 will see 1000 plus exhibitors and over 28000 visitors, from across the world.
How big is the India pharmaceutical and health care market? What is the trend observed? What are the challenges faced by the pharmaceutical and healthcare industry in India? What are your suggestions to overcome them, and how would the CPhI India 2014 play a role in it?
Now the tenth largest economy in the world and with global exports of around US$15 billion over the last 12 months, India is an innovation hub and a well-known focal point of the pharmaceutical industry and Mckinsey and Company forecast a staggering total value of US$45bn by 2020. Around 220 countries are sourcing pharma products from India, with the top 20 of India’s pharmaceutical companies contributing to almost two-thirds of the country’s total exports. These are exciting times for Indian pharmaceutical market as the global demand for Indian made drugs continues to rise, particularly with Western economies looking to further expand their use of generics.
Would like to re-iterate some of the key industry observations shared by our esteemed Jury for the India Pharma Awards 2014, during a recent jury meet. The Indian pharmaceutical sector is clearly growing, significantly contributing to the Indian economy and putting us on the global map. The sector is redefining itself, moving to ‘next practices’ from ‘best practices’, and some of the entries for the award clearly reflect this. India is constantly seeking to match and surpass western quality standards while maintaining lower manufacturing costs. There will be a strong thrust in the manufacturing arena in line with the national priority of ‘Make in India’.
Another key challenge faced by the industry is to reclaim the enviable reputation it had earned, which has unfortunately got tarnished. However, the industry recognizes the need of building quality culture and shunning complacency. Also, organisations are increasingly focusing on building the 3 Ps - People , Planet and Profit and have started recruiting Chief Sustainability Officers to give them a competitive edge.
CPhI 2014 will thus help provide a good insight into initiatives such as these in this area. The event will also elevate India as the global pharmaceutical destination by showcasing the unique positioning of the Indian pharma market and provide an optimum investment platform amidst its global counterparts.